HAPLN1

Across TCGA pan-cancer cohorts, HAPLN1 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated HAPLN1 data layer compared with 28 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher HAPLN1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated HAPLN1 expression acts as an unfavorable survival marker.

PDAC, LSCC, and CCRCC are the cancer types where HAPLN1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	All	0.686	0.942	.002	19	view →
LSCC	OS	Quartile	II,III,IV	0.642	0.998	.002	19	view →
CCRCC	OS	Quartile	All	0.878	1.000	.020	7	view →
LUAD	DFS	Tertile	All	0.903	0.987	.013	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

HAPLN1–PDAC (DFS)

Open the PDAC breakdown →